Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVXNASDAQ:BGMNASDAQ:GPCRNASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXABIVAX Société Anonyme$8.15+1.1%$6.26$4.77▼$14.71$517.00M0.01147,813 shs249,294 shsBGMQilian International Holding Group$13.09+1.6%$11.60$5.26▼$16.50$1.27B1.3826,899 shs93,063 shsGPCRStructure Therapeutics$21.47-2.4%$21.81$13.22▼$57.60$1.23B-1.69886,217 shs528,098 shsTVTXTravere Therapeutics$14.72-3.3%$17.08$6.80▼$25.29$1.31B0.751.59 million shs1.10 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXABIVAX Société Anonyme+4.13%+41.90%+13.20%-2.77%-39.53%BGMQilian International Holding Group-4.73%+11.41%+15.09%+21.72%+1,288,999,900.00%GPCRStructure Therapeutics+0.14%-0.90%-20.15%-6.50%-59.48%TVTXTravere Therapeutics-1.17%+1.81%-28.91%-19.64%+98.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVXABIVAX Société Anonyme2.7245 of 5 stars3.54.00.00.02.80.80.6BGMQilian International Holding GroupN/AN/AN/AN/AN/AN/AN/AN/AGPCRStructure Therapeutics1.9479 of 5 stars3.51.00.00.02.31.70.6TVTXTravere Therapeutics2.5262 of 5 stars4.42.00.00.01.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXABIVAX Société Anonyme 3.00Buy$31.00280.37% UpsideBGMQilian International Holding Group 0.00N/AN/AN/AGPCRStructure Therapeutics 3.00Buy$79.86271.95% UpsideTVTXTravere Therapeutics 2.87Moderate Buy$31.79115.94% UpsideCurrent Analyst Ratings BreakdownLatest ABVX, BGM, GPCR, and TVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025TVTXTravere TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/16/2025TVTXTravere TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.005/12/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $75.005/2/2025GPCRStructure TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.005/2/2025TVTXTravere TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.005/2/2025TVTXTravere TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$22.00 ➝ $23.004/30/2025ABVXABIVAX Société AnonymeJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$33.00 ➝ $33.004/23/2025TVTXTravere TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight4/22/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/14/2025TVTXTravere TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$47.00 ➝ $47.004/11/2025TVTXTravere TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXABIVAX Société AnonymeN/AN/AN/AN/A$3.37 per shareN/ABGMQilian International Holding Group$25.10M50.71N/AN/A$6.10 per share2.15GPCRStructure TherapeuticsN/AN/AN/AN/A$9.77 per shareN/ATVTXTravere Therapeutics$273.53M4.78N/AN/A$2.67 per share5.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXABIVAX Société Anonyme-$159.90MN/A0.00N/AN/AN/AN/AN/A8/11/2025 (Estimated)BGMQilian International Holding Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/AGPCRStructure Therapeutics-$89.62M-$0.87N/AN/AN/AN/A-16.37%-15.68%8/14/2025 (Estimated)TVTXTravere Therapeutics-$111.40M-$2.81N/AN/AN/A-137.90%-1,636.87%-55.95%7/30/2025 (Estimated)Latest ABVX, BGM, GPCR, and TVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GPCRStructure Therapeutics-$0.24-$0.27-$0.03-$0.27N/AN/A5/1/2025Q1 2025TVTXTravere Therapeutics-$0.55-$0.47+$0.08-$0.47$77.44 million$81.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXABIVAX Société AnonymeN/AN/AN/AN/AN/ABGMQilian International Holding GroupN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXABIVAX Société Anonyme0.483.04N/ABGMQilian International Holding GroupN/A3.392.82GPCRStructure TherapeuticsN/A27.6327.63TVTXTravere Therapeutics24.961.711.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXABIVAX Société Anonyme47.91%BGMQilian International Holding GroupN/AGPCRStructure Therapeutics91.78%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipABVXABIVAX Société AnonymeN/ABGMQilian International Holding Group58.66%GPCRStructure Therapeutics9.43%TVTXTravere Therapeutics4.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXABIVAX Société Anonyme6163.44 millionN/ANot OptionableBGMQilian International Holding Group29897.22 million2.48 millionN/AGPCRStructure Therapeutics13657.34 million51.86 millionOptionableTVTXTravere Therapeutics46088.81 million75.12 millionOptionableABVX, BGM, GPCR, and TVTX HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 5 at 9:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 4 at 12:40 PM | accessnewswire.comTravere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the InvestigationJune 4 at 10:00 AM | accessnewswire.comTravere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA CongressJune 3 at 4:30 PM | businesswire.comBronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Shareholders to Inquire about Securities InvestigationJune 3 at 10:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 3 at 9:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 2 at 1:30 PM | globenewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to ConnectJune 2 at 10:00 AM | accessnewswire.comUniversal Beteiligungs und Servicegesellschaft mbH Buys New Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)June 2 at 4:41 AM | marketbeat.comPublic Employees Retirement System of Ohio Raises Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)June 2 at 4:25 AM | marketbeat.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Reach OutJune 1, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 1, 2025 | prnewswire.comAnalysts Set Travere Therapeutics, Inc. (NASDAQ:TVTX) PT at $31.79June 1, 2025 | americanbankingnews.comLevi & Korsinsky Launches Fraud Investigation on Behalf of Travere Therapeutics, Inc. (TVTX) ShareholdersMay 30, 2025 | accessnewswire.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 30, 2025 | marketbeat.comLost Money on Travere Therapeutics, Inc. (TVTX)? Possible Fraud - Contact Levi & Korsinsky TodayMay 29, 2025 | accessnewswire.comTravere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationMay 29, 2025 | accessnewswire.comTVTX Investor Notice: Levi & Korsinsky Investigates Travere Therapeutics, Inc. for Securities Law ViolationsMay 28, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to ConnectMay 28, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXMay 27, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities InvestigationMay 27, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABVX, BGM, GPCR, and TVTX Company DescriptionsABIVAX Société Anonyme NASDAQ:ABVX$8.15 +0.09 (+1.12%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Qilian International Holding Group NASDAQ:BGM$13.09 +0.20 (+1.55%) Closing price 03:58 PM EasternExtended Trading$13.09 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Structure Therapeutics NASDAQ:GPCR$21.47 -0.53 (-2.41%) Closing price 04:00 PM EasternExtended Trading$21.65 +0.18 (+0.84%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Travere Therapeutics NASDAQ:TVTX$14.72 -0.50 (-3.29%) Closing price 04:00 PM EasternExtended Trading$14.79 +0.07 (+0.48%) As of 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
